NasdaqGS - Nasdaq Real Time Price USD

Sanofi (SNY)

Compare
58.13 -0.38 (-0.65%)
At close: September 10 at 4:00 PM EDT
57.97 -0.16 (-0.28%)
Pre-Market: 4:20 AM EDT
Loading Chart for SNY
DELL
  • Previous Close 58.51
  • Open 58.19
  • Bid 58.10 x 500
  • Ask 58.16 x 500
  • Day's Range 57.88 - 58.26
  • 52 Week Range 42.63 - 58.97
  • Volume 963,616
  • Avg. Volume 2,188,927
  • Market Cap (intraday) 146.949B
  • Beta (5Y Monthly) 0.42
  • PE Ratio (TTM) 31.25
  • EPS (TTM) 1.86
  • Earnings Date Oct 25, 2024
  • Forward Dividend & Yield 2.04 (3.50%)
  • Ex-Dividend Date May 9, 2024
  • 1y Target Est 59.89

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

www.sanofi.com

86,088

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SNY

View More

Performance Overview: SNY

Trailing total returns as of 9/11/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SNY
21.85%
CAC 40
1.69%

1-Year Return

SNY
13.07%
CAC 40
2.41%

3-Year Return

SNY
35.23%
CAC 40
11.28%

5-Year Return

SNY
61.45%
CAC 40
32.58%

Compare To: SNY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SNY

View More

Valuation Measures

Annual
As of 9/10/2024
  • Market Cap

    146.01B

  • Enterprise Value

    164.72B

  • Trailing P/E

    31.21

  • Forward P/E

    11.85

  • PEG Ratio (5yr expected)

    0.86

  • Price/Sales (ttm)

    2.78

  • Price/Book (mrq)

    1.81

  • Enterprise Value/Revenue

    3.15

  • Enterprise Value/EBITDA

    13.84

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    8.95%

  • Return on Assets (ttm)

    4.16%

  • Return on Equity (ttm)

    5.82%

  • Revenue (ttm)

    47.08B

  • Net Income Avi to Common (ttm)

    4.22B

  • Diluted EPS (ttm)

    1.86

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.79B

  • Total Debt/Equity (mrq)

    32.54%

  • Levered Free Cash Flow (ttm)

    4.6B

Research Analysis: SNY

View More

Company Insights: SNY

Research Reports: SNY

View More

People Also Watch